Home Health Pfitzer joins Spark Therapeutics in gene therapy to stop Hemophilia

Pfitzer joins Spark Therapeutics in gene therapy to stop Hemophilia


Scientists’ recent experiments on gene therapy are promising, especially since this has been in the works for over 20 years. These new studies are receiving positive feedback, and interest. One of the world’s leading drug companies, Pfizer, is teeming up with the Philadelphia based Spark Therapeutics, a privately owned U.S. biotech firm. The two are setting up SPK-FIX—a program that studies potential treatments for patients with hemophilia.

Hemophilia is a genetic anomaly that stops a person’s blood from coagulating (clotting) after a cut or wound. When blood does not clot, the wound cannot heal normally, and the individual is at risk of other illnesses associated with heavy loss of blood. The SPK-FIX focuses on hemophilia B with the use of adeno-associated virus (AAV) to manipulate the corrupted gene that causes bleeding.


Pfizer is well known for its long-term investment in fighting against hemophilia. For over 17 years, Pfizer has been providing hemophilia products to patients. Even further, Pfizer sports a global portfolio of 22 approved medicines that treat rare diseases in hematology, neuroscience, pulmonology, metabolic disorders, and oncology. This new research program is the next step in its commitment to improving the lives of blood illness victims.


During the first half of the new year, the initial stages of the program will begin. Spark Therapeutics will manage the first part of the program, phases I/II clinical trials; and Pfizer will take over later studies. On the forefront of the program is Michael Linden, a professor at King’s College, and director of the University College London Gene Therapy Consortium. Linden, who has wide-ranging research experience in AAV gene technology, has agreed to stay with the Pfizer for a two-year secondment to lead rare disease gene therapy.

Green Monday Deals on Fire HD 7, Fire Phone, TV, Laptops, Games, Tablets and more

Linden’s knowledge is critical in Pfizer’s program, because rare diseases are illnesses that affect millions of patients worldwide. Gene therapy, previously a long and disappointing study, has only recently reached gene-altering advancements that can be sold. A new gene therapy drug is scheduled to go on sale in Germany for $1.4 Million in 2015. The new drug battles a genetic disease called lipoprotein lipase deficiency (LPLD) that clogs the blood with fat. These advancements give encouragement to the SPK-FIX program.

Bristol-Myers Squibb’s Nivolumab can cure Hodgkin’s Lymphomia

Though the new developments in gene therapy are promising, the large price tag attached to them is very disheartening. The SPK-FIX program has the potential to completely alter defected genes in hemophilia patients, but its affordability is the next issue.

Previous articleApple releases best iPhone and iPad apps of the year list
Next articleMalaria averted 4.3 million deaths in between 2001-2013, says WHO
An entrepreneur by birth, blogger by choice, and geek by heart. He founded Sprouts Media, a blogs/websites network company, currently owns over 10 popular web properties, to cater his passion of journalism and entrepreneurship. He is also known as an avid reader, technology enthusiast, explorer, and a broken lover. His passion for knowledge keeps him running all the time. A pure vegetarian, who believes in reincarnation & law of karma and follows the philosophy of “Live and let others Live” because all living beings have equal right on the resources of this planet. He loves to write about Technology and Social Issues on his blogs. He can be reached at nitin [at] sprouts.media.